Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis.
OBJECTIVES: To determine the relation between intestinal barrier dysfunction, bacterial translocation, and clinical outcome in patients with predicted severe acute pancreatitis and the influence of probiotics on these processes. SUMMARY OF BACKGROUND DATA: Randomized, placebo-controlled, multicente...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2009
|
| _version_ | 1797064191907987456 |
|---|---|
| author | Besselink, MG van Santvoort, H Renooij, W de Smet, M Boermeester, M Fischer, K Timmerman, H Ahmed Ali, U Cirkel, G Bollen, T van Ramshorst, B Schaapherder, A Witteman, B Ploeg, R van Goor, H van Laarhoven, C Tan, A Brink, M van der Harst, E Wahab, P Eijck, v Dejong, C van Erpecum, K Akkermans, L Gooszen, H |
| author_facet | Besselink, MG van Santvoort, H Renooij, W de Smet, M Boermeester, M Fischer, K Timmerman, H Ahmed Ali, U Cirkel, G Bollen, T van Ramshorst, B Schaapherder, A Witteman, B Ploeg, R van Goor, H van Laarhoven, C Tan, A Brink, M van der Harst, E Wahab, P Eijck, v Dejong, C van Erpecum, K Akkermans, L Gooszen, H |
| author_sort | Besselink, MG |
| collection | OXFORD |
| description | OBJECTIVES: To determine the relation between intestinal barrier dysfunction, bacterial translocation, and clinical outcome in patients with predicted severe acute pancreatitis and the influence of probiotics on these processes. SUMMARY OF BACKGROUND DATA: Randomized, placebo-controlled, multicenter trial on probiotic prophylaxis (Ecologic 641) in patients with predicted severe acute pancreatitis (PROPATRIA). METHODS: Excretion of intestinal fatty acid binding protein (IFABP, a parameter for enterocyte damage), recovery of polyethylene glycols (PEGs, a parameter for intestinal permeability), and excretion of nitric oxide (NOx, a parameter for bacterial translocation) were assessed in urine of 141 patients collected 24 to 48 h after start of probiotic or placebo treatment and 7 days thereafter. RESULTS: IFABP concentrations in the first 72 hours were higher in patients who developed bacteremia (P = 0.03), infected necrosis (P = 0.01), and organ failure (P = 0.008). PEG recovery was higher in patients who developed bacteremia (PEG 4000, P = 0.001), organ failure (PEG 4000, P < 0.0001), or died (PEG 4000, P = 0.009). Probiotic prophylaxis was associated with an increase in IFABP (median 362 vs. 199 pg/mL; P = 0.02), most evidently in patients with organ failure (P = 0.001), and did not influence intestinal permeability. Overall, probiotics decreased NOx (P = 0.05) but, in patients with organ failure, increased NOx (P = 0.001). CONCLUSIONS: Bacteremia, infected necrosis, organ failure, and mortality were all associated with intestinal barrier dysfunction early in the course of acute pancreatitis. Overall, prophylaxis with this specific combination of probiotic strains reduced bacterial translocation, but was associated with increased bacterial translocation and enterocyte damage in patients with organ failure. |
| first_indexed | 2024-03-06T21:10:43Z |
| format | Journal article |
| id | oxford-uuid:3e108a33-5204-4824-820b-9d1557ac06bb |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:10:43Z |
| publishDate | 2009 |
| record_format | dspace |
| spelling | oxford-uuid:3e108a33-5204-4824-820b-9d1557ac06bb2022-03-26T14:23:23ZIntestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3e108a33-5204-4824-820b-9d1557ac06bbEnglishSymplectic Elements at Oxford2009Besselink, MGvan Santvoort, HRenooij, Wde Smet, MBoermeester, MFischer, KTimmerman, HAhmed Ali, UCirkel, GBollen, Tvan Ramshorst, BSchaapherder, AWitteman, BPloeg, Rvan Goor, Hvan Laarhoven, CTan, ABrink, Mvan der Harst, EWahab, PEijck, vDejong, Cvan Erpecum, KAkkermans, LGooszen, H OBJECTIVES: To determine the relation between intestinal barrier dysfunction, bacterial translocation, and clinical outcome in patients with predicted severe acute pancreatitis and the influence of probiotics on these processes. SUMMARY OF BACKGROUND DATA: Randomized, placebo-controlled, multicenter trial on probiotic prophylaxis (Ecologic 641) in patients with predicted severe acute pancreatitis (PROPATRIA). METHODS: Excretion of intestinal fatty acid binding protein (IFABP, a parameter for enterocyte damage), recovery of polyethylene glycols (PEGs, a parameter for intestinal permeability), and excretion of nitric oxide (NOx, a parameter for bacterial translocation) were assessed in urine of 141 patients collected 24 to 48 h after start of probiotic or placebo treatment and 7 days thereafter. RESULTS: IFABP concentrations in the first 72 hours were higher in patients who developed bacteremia (P = 0.03), infected necrosis (P = 0.01), and organ failure (P = 0.008). PEG recovery was higher in patients who developed bacteremia (PEG 4000, P = 0.001), organ failure (PEG 4000, P < 0.0001), or died (PEG 4000, P = 0.009). Probiotic prophylaxis was associated with an increase in IFABP (median 362 vs. 199 pg/mL; P = 0.02), most evidently in patients with organ failure (P = 0.001), and did not influence intestinal permeability. Overall, probiotics decreased NOx (P = 0.05) but, in patients with organ failure, increased NOx (P = 0.001). CONCLUSIONS: Bacteremia, infected necrosis, organ failure, and mortality were all associated with intestinal barrier dysfunction early in the course of acute pancreatitis. Overall, prophylaxis with this specific combination of probiotic strains reduced bacterial translocation, but was associated with increased bacterial translocation and enterocyte damage in patients with organ failure. |
| spellingShingle | Besselink, MG van Santvoort, H Renooij, W de Smet, M Boermeester, M Fischer, K Timmerman, H Ahmed Ali, U Cirkel, G Bollen, T van Ramshorst, B Schaapherder, A Witteman, B Ploeg, R van Goor, H van Laarhoven, C Tan, A Brink, M van der Harst, E Wahab, P Eijck, v Dejong, C van Erpecum, K Akkermans, L Gooszen, H Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis. |
| title | Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis. |
| title_full | Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis. |
| title_fullStr | Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis. |
| title_full_unstemmed | Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis. |
| title_short | Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis. |
| title_sort | intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis |
| work_keys_str_mv | AT besselinkmg intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT vansantvoorth intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT renooijw intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT desmetm intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT boermeesterm intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT fischerk intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT timmermanh intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT ahmedaliu intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT cirkelg intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT bollent intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT vanramshorstb intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT schaapherdera intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT wittemanb intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT ploegr intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT vangoorh intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT vanlaarhovenc intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT tana intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT brinkm intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT vanderharste intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT wahabp intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT eijckv intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT dejongc intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT vanerpecumk intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT akkermansl intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis AT gooszenh intestinalbarrierdysfunctioninarandomizedtrialofaspecificprobioticcompositioninacutepancreatitis |